Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppre

AnHorn’s flagship therapeutic modality is BIGPRO®, a bi‑functional ligand that induces targeted degradation of disease-causing proteins. Using their proprietary AIMCADD® platform (which integrates AI, bioinformatics, and medicinal chemistry), AnHorn rapid

GenomeFrontier’s product pipeline is built around its Quantum Engine™, which integrates four core platforms: Quantum Nufect™ (gentle, efficient gene delivery), Quantum pBac™ (high-capacity non-viral gene integration), iCellar™ (robust cell expansion), and

Ochre Bio’s key technology pillars include a Human Discovery Platform (combining patient liver data with gene perturbation atlases), a Human Validation Platform (using perfused livers, diseased tissue slices, and primary cells), and an RNA Therapeutics Pl